FFRct: From FDA De Novo to Billion Dollar Routine Referral

Getting a new cardiac diagnostic from a research paper into a routine clinical referral is anything but a straight line. You need rock-solid science, yes, but you also have to get regulatory clearance, secure reimbursement, and then build trust with long-term evidence. For anyone leading an interventional or imaging cardiology program and sorting through the flood of new cardiovascular AI, the story of coronary CT-derived fractional flow reserve (FFRct) is a perfect case study.

The De Novo Pathway and the Genesis of FFRct

The first real breakthrough for non-invasive FFRct was getting through the FDA’s De Novo Pathway. Think of this route as the FDA’s front door for truly new, low-to-moderate risk devices that have no existing predicate to compare against, which means the FDA has to create a whole new device classification for them. This is completely different from the typical 510(k) clearance, where you just have to prove your device is “substantially equivalent” to something already on the market. HeartFlow got the first-ever De Novo clearance for its non-invasive FFRct analysis, which effectively set the regulatory precedent for this entire class of advanced cardiac imaging AI. By giving FFRct a De Novo classification, the FDA was signaling that this was genuinely new technology with real clinical potential. That initial FDA De Novo Pathway, which created the FFRct classification, along with the later 510(k) clearances that followed for similar tools, is still the main regulatory gate these imaging and monitoring technologies have to pass through to get into clinical practice. This history is important because it gives today’s cardiac AI startups a playbook for working through the US regulatory environment.

From Clearance to Coverage: Securing National Reimbursement

FDA clearance is just the first hill to climb. A technology doesn’t become routine until someone agrees to pay for it. HeartFlow really cemented FFRct’s clinical future when it secured a CMS National Coverage Determination (NCD) for FFRct. This NCD meant that FFRct analysis now had national coverage, transforming it from a tool used mostly in research studies into a diagnostic test that could be reimbursed for eligible Medicare patients. This was the ballgame. It created a clear payment pathway, which is the number one thing a healthcare system needs to see before it will even consider integrating an advanced diagnostic like this. Getting national reimbursement for FFRct was what truly opened the door for it to be used widely. The one-two punch of a De Novo clearance followed by a national coverage determination shows the tough but essential path any new cardiac AI tech has to follow to become a standard, referrable test.

The Long View: Evidence and Trust through Extended Follow-Up

Even with regulatory and reimbursement wins, doctors won’t trust a new diagnostic without seeing how it performs over the long haul. For CT-derived FFR, the ten-year PLATFORM follow-up study gave referring cardiologists a huge window of evidence, backing up its value in guiding patient management. At the same time, a health technology appraisal from the United Kingdom, known as HTG429, added to the growing international evidence base that supported the tech. These long-term studies and independent evaluations are what show the real-world impact and consistent value of cardiac AI solutions. As coronary CT angiography programs grew more sophisticated, they saw AI plaque quantification go from something you’d only see in a research scan to a topic of conversation for routine referrals. This shift was helped along by risk prediction models built on the very same datasets, showing just how deeply AI was getting integrated into how we interpret images and predict outcomes. That full decade of evidence is what it takes to really change clinical habits and build confidence among the program leads in interventional and imaging cardiology.

Expanding the Modality: AI Plaque Analysis and Ambulatory Monitoring

The FFRct playbook worked so well that it cleared a path for other kinds of AI to be used on the same coronary CT scans. Cleerly, for instance, built a whole business around its independent plaque analysis software, which uses AI to measure and characterize the amount of coronary plaque from a standard CT angiogram. It’s a different but complementary use of AI in cardiac imaging that digs into detailed anatomical assessment for risk stratification. Instead of just seeing if there’s a stenosis, you get a much richer picture of the actual coronary artery disease by characterizing the plaque itself. We’ve seen a similar pattern of evidence-building extend into ambulatory rhythm monitoring, too. iRhythm Technologies showed how AI can make the detection and diagnosis of arrhythmias much better through long-term ambulatory monitors. While it’s a completely different modality, iRhythm’s strategy for generating evidence and driving clinical integration looks a lot like the path blazed by cardiac imaging AI. It all comes down to the same thing: you need strong validation and obvious clinical benefit to get doctors to use it and to penetrate the market. The FDA De Novo pathway that created the FFRct classification, alongside the later 510(k) clearances recorded on the same modality, remains the common regulatory gate through which these imaging and monitoring tools enter clinical use. The whole cardiac AI market funding distribution shows that diagnostic AI is attracting serious money precisely because these regulatory pathways and evidence requirements are now so well-defined.

The Referral Shift: From Research to Routine

When you line up FDA clearance, national insurance coverage, and a decade of solid clinical data, you fundamentally change the referral pathways for coronary CT. The non-invasive FFRct analysis that started out as a technique for research studies has now become a routine diagnostic test. Why the change? It’s a direct result of the powerful evidence showing it works and the fact that there are established ways to get paid for it. For interventional and imaging cardiology program leads, there’s now a clear framework for how to bring these advanced cardiac AI tools into their own diagnostic workflows. The whole story of FFRct provides a working blueprint for the next wave of cardiac AI products, proving that you need a complete strategy covering validation, reimbursement, and long-term evidence if you want to see your tech actually get used.